Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jennifer, Leohr"'
Autor:
Jennifer Leohr, Maria C. Kjellsson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1529-1540 (2023)
Abstract The TIGG model is the first model to integrate glucose and insulin regulation, incretin effect, and triglyceride (TG) response in the lipoprotein subclasses of chylomicrons and VLDL‐V6. This model described the response following a high‐
Externí odkaz:
https://doaj.org/article/a840e8429e754b49abbd787a0d074e29
Autor:
Jennifer, Leohr, Maria C, Kjellsson
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:112-124
The integrated glucose-insulin model is a semimechanistic model describing glucose and insulin after a glucose challenge. Similarly, a semiphysiologic model of the postprandial triglyceride (TG) response in chylomicrons and VLDL-V6 was recently publi
Autor:
null Ronnie Aronson, null Torben Biester, null Jennifer Leohr, null Robyn Pollom, null Helle Linnebjerg, null Elizabeth Smith LaBell, null Qianyi Zhang, null David E Coutant, null Thomas Danne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89d871627c74fbaf9fcf70cab4601d97
https://doi.org/10.1111/dom.15063/v2/response1
https://doi.org/10.1111/dom.15063/v2/response1
Autor:
Christof M. Kazda, Jennifer Leohr, Thomas A. Hardy, Mary Anne Dellva, Christoph Kapitza, Mark Matzopoulos, Mei Teng Loh, Rong Liu, Shobha Reddy, Oliver Klein
Publikováno v:
Diabetes, Obesity and Metabolism. 24:187-195
AIMS To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes mellitus (T2D). MATERIALS AND METHODS Th
Autor:
Mary Anne Dellva, Jennifer Leohr, Shobha Reddy, Christof M. Kazda, Thomas Hardy, Mei Teng Loh, Rong Liu, Leona Plum-Mörschel
Publikováno v:
Diabetes, Obesity and Metabolism. 24:196-203
Aim This study compared the pharmacokinetics (PK), glucodynamics (GD), and tolerability following single and multiple daily subcutaneous (SC) doses of ultra rapid lispro (URLi) and Humalog in patients with type 1 diabetes mellitus (T1D). Materials an
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and
Autor:
Jennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, Zhentao Tong, Jorge Arrubla, Leona Plum-Mörschel, Eric Zijlstra, Tsuyoshi Fukuda, Thomas Hardy, Bernhard Gehr
Publikováno v:
Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.
Publikováno v:
Diabetes Therapy
Introduction Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the bioequivalence (BE) of a concentrated formulation (U
Autor:
Eric Zijlstra, Christoph Kapitza, Qianyi Zhang, Helle Linnebjerg, Juliana M. Bue-Valleskey, David E. Coutant, Jennifer Leohr, Tim Heise, Elizabeth Smith Labell, Mary Anne Dellva
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (
Autor:
Theresa Herbrand, Ulrike Hövelmann, David E. Coutant, Jennifer Leohr, Qianyi Zhang, Leona Plum-Mörschel, Mary Anne Dellva, Elizabeth Smith Labell, Helle Linnebjerg
Publikováno v:
Clinical Pharmacokinetics
Background Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the pharmacokinetics, glucodynamics, safety, and